| Src family kinases are essential for primary aggregation by G(i) -coupled receptors. | |
| | |
MedLine Citation:
|
PMID: 20738760 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION AND BACKGROUND: Adrenaline stimulates biphasic aggregation in plasma through the G(i) -coupled α(2A) -adrenoreceptor. In the present study, we demonstrate that both primary and secondary wave aggregation induced by adrenaline in plasma is blocked by two structurally distinct inhibitors of Src family kinases, dasatinib and PD0173952. METHODS AND RESULTS: In contrast, primary aggregation is partially inhibited or unaffected in the presence of inhibitors of cyclo-oxygenase, phosphoinositide (PI) 3-kinases, and P2Y(1) and P2Y(12) ADP receptors, although secondary aggregation is abolished. The ability of adrenaline to inhibit adenylyl cyclase and to synergize with platelet agonists in mediating platelet activation in plasma is retained in the presence of Src family kinase inhibition. Moreover, adrenaline does not activate Src family kinases, as determined by western blotting of their regulatory tyrosines, suggesting that constitutive signaling from Src family kinases may underlie their role in activation. Adrenaline is widely used in clinical laboratories for investigation of patients with suspected bleeding disorders. In a group of 90 unrelated patients with a clinically diagnosed platelet bleeding disorder, we identified four who did not exhibit primary wave aggregation in response to adrenaline, although the catecholamine potentiated the response to other agonists, and five who failed to undergo secondary wave aggregation. In contrast, adrenaline stimulated biphasic aggregation in 60 controls. All of the patients with a defective response to adrenaline had impaired ADP-induced platelet activation. CONCLUSIONS: The present results indicate a previously unappreciated role for Src family kinases in mediating G(i) signaling in plasma, and demonstrate heterogeneity in response to adrenaline in patients with a clinically diagnosed platelet disorder. |
| | |
Authors:
|
C A Nash; S Séverin; B B Dawood; M Makris; A Mumford; J Wilde; Y A Senis; S P Watson |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of thrombosis and haemostasis : JTH Volume: 8 ISSN: 1538-7836 ISO Abbreviation: J. Thromb. Haemost. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-28 Completed Date: 2011-03-07 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 101170508 Medline TA: J Thromb Haemost Country: England |
Other Details:
|
Languages: eng Pagination: 2273-82 Citation Subset: IM |
Copyright Information:
|
© 2010 International Society on Thrombosis and Haemostasis. |
Affiliation:
|
Centre for Cardiovascular Sciences, Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, UK. can562@bham.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aza Compounds
/
pharmacology Blood Platelets / cytology, metabolism Cyclic AMP / metabolism Epinephrine / metabolism GTP-Binding Protein alpha Subunits, Gi-Go / metabolism* Humans Morpholines / pharmacology Phosphatidylinositol 3-Kinases / metabolism Phosphorylation Platelet Activation Platelet-Rich Plasma / metabolism Protein Kinase Inhibitors / pharmacology Pyrimidines / pharmacology Receptors, Purinergic P2Y12 / metabolism Thiazoles / pharmacology Tyrosine / chemistry src-Family Kinases / physiology* |
| Grant Support | |
ID/Acronym/Agency:
|
FS/08/023/25089//British Heart Foundation; PG/06/038//British Heart Foundation; PG/06/129//British Heart Foundation; RG/09/007//British Heart Foundation |
| Chemical | |
Reg. No./Substance:
|
0/8-(2,6-dichlorophenyl)-10-methyl-3-((4-morpholin-4-ylphenyl)amino)-2,4,10-triazabicyclo(4.4.0)deca-1,3,5,7-tetraen-9-one; 0/Aza Compounds; 0/Morpholines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/Receptors, Purinergic P2Y12; 0/Thiazoles; 51-43-4/Epinephrine; 55520-40-6/Tyrosine; 60-92-4/Cyclic AMP; EC 2.7.1.-/Phosphatidylinositol 3-Kinases; EC 2.7.10.2/src-Family Kinases; EC 3.6.5.1/GTP-Binding Protein alpha Subunits, Gi-Go; RBZ1571X5H/dasatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study.
Next Document: Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation ...